ANTHONY ZERANGUE: Open Payments
NPI 1477523538 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,140 in 184 payments from 24 companies in 2025. Trend: 2023 $4,048 · 2024 $3,854 · 2025 $4,140
Food & beverage: $4,140
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 35 | $1,148 |
| ABBVIE INC. | 23 | $614 |
| Lundbeck LLC | 23 | $372 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $223 |
| Paratek Pharmaceuticals, Inc. | 10 | $192 |
| Almatica Pharma LLC | 8 | $189 |
| Novo Nordisk Inc | 9 | $184 |
| PFIZER INC. | 13 | $173 |
| Axsome Therapeutics, Inc. | 9 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $150 |
Products named: BREZTRI, AIRSUPRA, REXULTI, VRAYLAR, LOREEV XR, XIFAXAN, NUZYRA, QULIPTA.
Industry payments across LA — which companies pay providers there.
